NCT02585947 - To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

June 30, 2018

Study Completion Date

September 30, 2018

Conditions

Non-Hodgkin's Lymphoma, Burkitt's

Interventions

DRUG

Tenofovir

Anti-HBc positive patients with Non-Hodgkin's lymphoma planned to receive rituximab based chemotherapy will be randomized to either Group A or Group B in a 1:1 ratio and will be monitored every 12 weeks from the start of treatment for up to 72 weeks after the end of chemotherapy (EOC).

Trial Locations (1)

"ASI

RECRUITING

Seoul National University, Seoul